

First Annual Multidisciplinary Endocrine Tumor Symposium

"Radioactive Iodine For Thyroid Cancer: Guidelines, Controversies, And Practical Lessons"

Friday, June 4, 2021

Virtual Conference via Zoom

Course Director: Shelby Holt, M.D.

**Sponsored by the UT Southwestern Department of Endocrine Surgery
and the UT Southwestern Office of Continuing Medical Education**

PURPOSE AND CONTENT

This live virtual CME activity is designed to provide physicians, nurses, and healthcare professionals in the specialties of endocrinology, medical oncology, radiation oncologist and surgical oncology. Didactic presentations will provide a comprehensive review of current guidelines regarding the use of radioactive iodine (RAI) for thyroid cancer, as well as case presentations offering practical lessons and application of the current guidelines.

Professional Practice Gap

The guidelines for use of radioactive iodine treatment (RAI) in patients with thyroid cancer have evolved significantly over the decades. For example, RAI was routine for all patients with follicular cell derived thyroid cancer 30 years ago; whereas current guidelines recommend highly selective use. Ever changing guidelines plus multiple different specialty providers involved in the treatment of thyroid cancer (particularly the case in North Texas where surgeons, endocrinologists, medical oncologists, and radiation oncologists may be primarily responsible for any given thyroid cancer patient) increases inconsistencies and confusion in optimal care which negatively impacts patient outcomes.

Educational Need

Evaluate current and evolving guidelines for the use of RAI and determine how RAI could be applied (or should not be applied) in specific patient modalities, in light of:

- 1) 2015 ATA guidelines on RAI dosing;
- 2) Martinique principles for RAI treatment (remnant ablation, adjuvant therapy, treatment of known disease);
- 3) Thyrogen stimulation versus thyroid hormone withdrawal stimulation for RAI;
- 4) Optimal preparation with low iodine diet and counseling on radiation safety for outpatient treatment;
- 5) Utility of pre-treatment scanning with low dose I131 versus I123; and
- 6) Use of dosimetry to guide RAI dosing.

Educational Objective

Identify and interpret current and evolving RAI guidelines and best practices, including: patient preparation, radiation safety, dosimetry, optimal scanning technique.

Desired Result

Expand application of RAI for individual patient management to ensure data driven, standard of care is being administered to promote best patient outcomes.

ACCREDITATION AND DESIGNATION STATEMENTS

Accreditation

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designations

Physicians

The University of Texas Southwestern Medical Center at Dallas designates this continuing education activity for a maximum of **2.75 AMA PRA Category 1 Credits™**. Each physician should claim only the credit commensurate with the extent of the participation in the activity.

Non-Physicians

The University of Texas Southwestern Medical Center certifies that non-physicians will receive an attendance certificate stating that they participated in the activity that was designated for a maximum of **2.75 AMA PRA Category 1 Credits™**.

EVALUATIONS AND CERTIFICATES

CME Certificates (Physicians) and Certificates of Attendance (Non-Physicians) are available online after the electronic evaluation is completed. This evaluation is an important tool for assessing the effectiveness of this activity as well as for planning future activities.

Next week, all attendees will receive an email with a link to access the evaluation. Once the evaluation is completed, attendance can claim credit (CME, Attendance) and view/download/print certificate.

DISCLAIMER

This symposium has been planned to be well-balanced and objective in discussion of comparative treatment regimens, and the symposium format allows for the free scientific exchange of ideas. Information and opinions offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.

DISCLOSURE OF UNLABELED USES

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians' Desk Reference.

FACULTY

Course Director

Shelby Holt, M.D.

Chief, Division of Endocrine Surgery
Professor, Department of Surgery
UT Southwestern Medical Center
Dallas, TX

Moderator

David McFadden, M.D., Ph.D.

Assistant Professor of Internal Medicine and Biochemistry
UT Southwestern Medical Center
Dallas, TX

Guest Speakers

Anca Avram, M.D.

Clinical Professor, Radiology
Director, Nuclear Medicine Medical Student Education
University of Michigan
Ann Arbor, MI

Michael Tuttle, M.D.

Professor of Medicine
Cornell University
Clinical Director, Endocrine Service
Memorial Sloan Kettering Hospital
New York, NY

DISCLOSURE OF COMMERCIAL INTEREST

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), The University of Texas Southwestern Medical Center, Office of Continuing Medical Education (UTSW CME) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of a commercial entity and promote improvements or quality in healthcare.

All persons in the position to control the content of an education activity are required to disclose all relevant financial relationships in any amount occurring within the past 12 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients.

The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The UTSW Office of CME has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity. The intent of this policy is to identify potential conflicts of interest so participants can form their own judgments with full disclosure of the facts.

Course Director/Speaker/Planner Names	Disclosure of Relevant Financial Relationships
Shelby Holt, M.D. (Course Director) David McFadden, M.D., Ph.D. (Moderator, Planner) Anca Avram, M.D. (Speaker) Michael Tuttle, M.D. (Speaker) Orhan Oz, M.D., Ph. D. (Planner) Gabby Hernandez (Planner) Mark Vinciguerra (CME Program Coordinator)	All reported having no relevant financial relationships

FIRST ANNUAL UT SOUTHWESTERN ENDOCRINE TUMOR SYMPOSIUM
FRIDAY, JUNE 4, 2021

AGENDA

- 12:45 PM ***Participants to join Zoom***
- 12:55 PM ***Welcome & Introduction***
 – Course Director: Shelby Holt, M.D.
- 1:00 PM ***“De-escalating Radioactive Iodine in Patients with Differentiated Thyroid Cancer: When to Use It And How Much?”***
 – Michael Tuttle, M.D.
- 1:30 PM ***“Radioiodine Treatment for Thyroid Cancer: Why, When, and How”***
 – Anca Avram, M.D.
- 2:00 PM ***Q & A Session With Our Guest Speakers***
 – Moderator: David McFadden, M.D., Ph.D.
- 2:20 PM ***Break***
- 2:30 PM ***Case Presentations***
 – Moderator: David McFadden, M.D., Ph.D.
- 4:00 PM ***Adjourn***
-